Acridinium Label Patents: Top Companies & Filing Trends 2026
- 36.9% concentration. The top five assignees hold 134 of 363 records in scope — a field with a clear leading cluster rather than pure fragmentation.
- Growth resumed 2021-2024. Filings rose from 16 to 19 a year across that span, a 19% increase, after 2023 marked the peak year so far at 34.
- Detection chemistry outweighs the label itself. G01N and C12Q each appear in over 43% of the 363 records, ahead of the core peptide and organo-metallic label classes.
Filing growth compares 2021 (16 records) with 2024 (19) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 363 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
This landscape tracks patent families combining acridinium ester labels and chemiluminescent substrates with the operational problems that determine whether an assay actually works in a cartridge or a plate reader: light emission kinetics, background luminescence, label stability, glow signal behaviour, conjugation ratio and reagent shelf life. It sits inside in vitro diagnostics but reaches into therapeutic antibody work, because many of the same conjugation and stability claims appear in both detection reagents and biologic drug candidates.
363 records are in scope, spanning filings from 2015 through the 2026-07-31 cut-off. Publication lags filing by roughly 18 months, so the last one to two years in any trend understate real filing activity rather than signal a slowdown.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trend and technology mix
Two views of the same 363 records: activity over time, and the IPC subclasses that carry the claims.
Filing activity, 2017-2026
Filings climbed from 6 in 2017 to a peak of 34 in 2023, then eased in the partial years that follow. The 2021-2024 span shows real growth — 16 to 19 filings, +19% — and the 2025-2026 dip reflects publication lag rather than a genuine drop in activity.
Technology composition by IPC subclass
G01N (material analysis, 43.5% of the 363 records) and C12Q (enzymatic/DNA measurement, 43.0%) lead, with C07K peptide chemistry close behind at 41.3%. The smaller organo-metallic class C07F, at 7.7%, is where the acridinium label chemistry itself is most narrowly claimed — everything above it concerns how the label is used, not what it is.
Shares are the percentage of the 363 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Acridinium and Enzymatic Label Chemistry with Eureka
This page is one run against one query. Ask Eureka your own question about acridinium and enzymatic label chemistry and every answer comes back with the patent numbers behind it.
Try EurekaRepresentative and most-cited filings
Chemiluminescent substrate solution and chemiluminescence detection method (US20250216403A1)
The disclosure covers a chemiluminescent substrate solution combining a chemiluminescent substrate selected from chlorinated dioxetane compounds with a spiroadamantane substituent, a fluorescein, and a water-soluble polymeric quaternary ammonium salt, giving a wider linear detection range.Filed by Shenzhen Mindray Bio-Medical Electronics, published 2025-07-03 — illustrates how current filings combine substrate chemistry with formulation additives rather than claiming the acridinium label alone.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US5283174A | Homogenous protection assay | 993 |
| 2 | US9371394B2 | Monoclonal antibodies and detection methods for phosphinothricin-N-acetyl-transferase enzyme | 650 |
| 3 | US5639604A | Homogeneous protection assay | 540 |
| 4 | US20030054396A1 | Enzymatic light amplification | 199 |
| 5 | WO1989002476A1 | Homogeneous protection assay | 179 |
| 6 | US5112960A | Chemiluminescent 3-(substituted adamant-2'-ylidene) 1,2-dioxetanes | 141 |
| 7 | US6004745A | Hybridization protection assay | 137 |
| 8 | US5216126A | Receptor polypeptides and their production and uses | 128 |
| 9 | US6586196B1 | Multiple enzyme assays | 75 |
| 10 | US5543295A | Chemiluminescent 3-(Substituted adamant-2'-Ylidene) 1,2-Dioxetanes | 72 |
Citation counts favour older filings that have had more time to accumulate citations inside this corpus; treat them as a signal of influence on the field, not of current commercial weight.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for filing strategy
Three patterns stand out once the ranking, the trend and the IPC mix are read together.
A leading cluster, not a monopoly
The top five assignees hold 134 of the 363 records in scope, and the top ten extend that to 59.8% (217 records). That leaves a long tail of single- and few-filing entrants below tenth place, where the leader alone holds 34 records against 12 at tenth.
Growth is real but recent years are incomplete
The 2021-2024 span shows filings rising from 16 to 19 a year, and 2023 remains the peak year so far at 34. The apparent drop into 2025-2026 is a publication-lag artefact, not evidence the field is cooling.
Assay mechanics dominate over label chemistry
G01N and C12Q each cover over 43% of records, while the core organo-metallic label class C07F sits at just 7.7%. Most claim activity is happening around how the label performs in an assay, not around new acridinium chemistries themselves.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to acridinium and enzymatic label chemistry, with the prior art for and against each one.
Who is filing, and where the field is still open
The ranked leaders sit alongside co-filing pairs and a set of branches that remain lightly claimed.
A clear leader with a steep drop-off
The top-ranked assignee holds 34 records against 23 at fifth place and 12 at tenth, a steep gradient that suggests early, broad claiming rather than a crowded contest among equals.
One dominant collaboration pair
Ten co-assignee pairs appear in the dataset, but one pair — the University of Pennsylvania trustees and Kite Pharma — accounts for 22 shared records, far ahead of the next pairs at two records each.
Recent-year activity has gone quiet at the top
The most recent-year movers show flat or negative year-on-year change, including two leading pairs at -100% YoY. That pattern is consistent with publication lag rather than genuine withdrawal from the field.
| Assignee | Recent year | YoY |
|---|---|---|
| TeneoBio Inc | 1 | 0% |
| Genmab BV | 1 | 0% |
| Gen-Probe Inc | 0 | — |
| Digene Corp | 0 | — |
| The Trustees of the University of Pennsylvania | 0 | -100% |
| Kite Pharma Inc | 0 | -100% |
| Life Technologies Corp | 0 | -100% |
| Kisoji Biotechnology Inc | 0 | -100% |
Where to take this next
The dataset points to specific follow-up questions rather than a single conclusion.
Check freedom to operate against the leading cluster
With 36.9% of records held by five assignees, a new filing in core acridinium label chemistry should be checked against that cluster before drafting claims.
Run a freedom-to-operate search in EurekaWatch the 2025-2026 publication window
Apparent declines in the last two years are a publication-lag effect. Revisit the trend once those years mature before drawing conclusions about slowing activity.
Track filing trends in EurekaExplore the under-claimed branches
Formulation additives and reagent stability sit behind the dominant assay-mechanics classes in filing density, and may offer more open claim space.
Explore white space in EurekaCommon questions on this landscape
The dataset ranks 100 assignees by record count, with the leader holding 34 of the 363 records in scope and the top five combined holding 134 records, or 36.9% of the field. That concentration drops off sharply after the top ten, which together hold 59.8% of records, leaving a long tail of assignees with only one or a handful of filings each. This pattern suggests early, broad claiming by a small group rather than an evenly contested field.
Filings grew from 16 in 2021 to 19 in 2024, a 19% increase over that span, with 2023 marking the peak year so far at 34 filings. The apparent decline visible in 2025 and 2026 is a publication-lag artefact — patent applications typically publish around 18 months after filing, so the most recent one to two years always look understated. Treat 2024 as the last complete year when judging the real trend.
The filing, from Shenzhen Mindray Bio-Medical Electronics and published 2025-07-03, claims a chemiluminescent substrate solution built from chlorinated dioxetane compounds with a spiroadamantane substituent, combined with a fluorescein and a water-soluble polymeric quaternary ammonium salt. It is a formulation claim covering that specific combination, aimed at achieving a wider linear detection range. It does not block acridinium ester chemistry generally, but anyone formulating a similar dioxetane-plus-polymer substrate mix should review it directly rather than assume clearance.
Material analysis and testing (G01N) and enzymatic/DNA measurement (C12Q) are the two most heavily claimed classes, each appearing in over 43% of the 363 records in scope, with peptide and protein chemistry (C07K) close behind at 41.3%. The core organo-metallic label chemistry class (C07F) is comparatively thin at 7.7% of records. That gap means most of the crowded claim space concerns how labels are used and detected in an assay, not the underlying acridinium chemistry itself.
The clearest openings sit in formulation-level claims — spiroadamantane dioxetane substrate chemistry, polymeric quaternary ammonium enhancers, and reagent shelf-life stabilisation — where filing density is lower than in the dominant assay-mechanics classes. Conjugation-ratio control for antibody-label stability and glow-signal kinetics in cartridge-based readers are similarly less densely claimed. A first claim in these branches should specify the formulation component and its measurable effect (e.g. linear range, background suppression) rather than claiming the label chemistry broadly, since that ground is already occupied by the leading assignees.
Research Acridinium and Enzymatic Label Chemistry in depth with Eureka
Go past this page: query the whole acridinium and enzymatic label chemistry corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.